Get the Stockscreener App
0.00
100.00%
-28.56
After Hours:
27.86
27.86
+
Vyne Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$28.56
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$19.07M
Revenue:
$454.00K
Net Income/Loss:
$-21.72M
P/E Ratio:
0.00
EPS:
-0.5337
Net Cash Flow:
$-25.74M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$46.95
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.00 | 19.07M | 454.00K | -21.72M | -25.74M | -0.5337 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
Vyne Therapeutics Inc (NASDAQ: VYNE) Share Price, VYNE Stock News, VYNE Share Price & Updates - Kalkine
VYNE Therapeutics (VYNE) Holds Flat at $28.56 as Shares Sit Mid-Range Between Key Technical Levels - dars.gov.et
VYNE stock holds at $28.56 as investors await the next data catalyst - AD HOC NEWS
VYNE Special Dividend Tied To Merger: My Take On The 8-K Learn (V8sbUVk4ib) - Mshale
VYNE (VYNE) Levels: Trades in a Narrow Directional Range at $28.56 in the Latest Session; Technical Setup: $27.13 and $29.99 Define the Nearby Reference Levels in Latest TradingVolatility Term Structure - vinanet.vn
VYNE (VYNE) Trading-Day Recap: Closes with Limited Movement at $28.56 in the Current Update; Price-Level Context: Price Remains Between $27.13 Support and $29.99 Resistance in Latest TradingSynthetic Long - vinanet.vn
Rachael Alford Net Worth (2026) - GuruFocus
Lori Payton Net Worth (2026) - GuruFocus
New Haven biotech goes public after merger, raises $200M - Hartford Business Journal
VYNE Therapeutics (VYNE) Consolidates at $28.56 as Key Support and Resistance Levels Define Trading RangeTrade Entry Signals - vinanet.vn
Yarrow Bioscience (VYNE) halves losses and completes transformative merger with Yarrow - Stock Titan
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
ORBIMED ADVISORS LLC Buys VYNE Therapeutics Inc (VYNE) -- Shares Look 27% Overvalued on GF Value - GuruFocus
VYNE Q1 2026 Earnings: Narrower-Than-Expected -$4.00 Per Share Loss Delivers 56.43% Surprise - vinanet.vn
Top Portage Biotech (ALP) Competitors 2026 - MarketBeat
Yarrow Bioscience (VYNE): Logos group discloses 10.7% ownership and large warrants - Stock Titan
OrbiMed Advisors Discloses Investment at Yarrow Bioscience with 9.97% Stake - TradingView
OrbiMed discloses sub-10% Yarrow Bioscience, Inc. (Ticker: VYNE) stake and large warrants - Stock Titan
Yarrow Bioscience (VYNE) sees 9.9% ownership stake from Logos Global funds - Stock Titan
Biotech Stocks At 52-Week HighsANGO, ANIK, ELOX, YARW, PLSE - RTTNews
VYNE Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 56.43% Positive SurpriseEarnings Manipulation Risk - vinanet.vn
RTW group discloses 266,307-share, 9.99% holding in Yarrow Bioscience (VYNE) - Stock Titan
Vyne Therapeutics issues pre-funded warrants for 133,290 shares in stock exchange deal - Bitget
Yarrow Bioscience (YARW) Stock Price, News & Analysis - MarketBeat
Yarrow Bioscience, Inc. (VYNE) director reports large OrbiMed warrants - Stock Titan
YARWYarrow Bioscience Inc Stock Price and Quote - Finviz
Yarrow Bioscience closes VYNE merger and $200 million financing - Quiver Quantitative
Net income before discontinued operations of VYNE Therapeutics Inc. – NASDAQ:YARW - TradingView
VYNE Therapeutics Inc. Earnings and Revenue – NASDAQ:YARW - TradingView
VYNE Therapeutics Inc. Balance Sheet – NASDAQ:YARW - TradingView
Vyne Therapeutics Inc (VYNE) Institutional Confidence - TradingKey
Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101 - Moomoo
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Business Wire
VYNE|Vyne Therapeutics Inc|Price:0.509|Chg%:-0.012 - TradingKey
VYNE|Vyne Therapeutics Inc|Price:28.560|Chg%:+28.051 - TradingKey
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut - TipRanks
Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VYNE|Vyne Therapeutics Inc|Price:28.560| - TradingKey
Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vyne Therapeutics Inc (VYNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
VYNE Q1 2026 Earnings: EPS Beats Estimates Amid Steep Stock DeclineRevenue Miss Report - vinanet.vn
Vyne Therapeutics Provides Update Regarding C - Moomoo
Form 4 Vyne Therapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria
VYNE Therapeutics (Ticker: VYNE) CFO reports tax-share withholding event - Stock Titan
Tax withholding trims stake of VYNE Therapeutics Inc. (VYNE) CSO - Stock Titan
VYNE Therapeutics (VYNE) CLO has shares withheld for RSU taxes - Stock Titan
VYNE Therapeutics Inc. Revenue Breakdown – NASDAQ:VYNE - TradingView
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - marketscreener.com
Press Release: VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger With Yarrow Bioscience - Moomoo
VYNE Therapeutics To Go Ex-Dividend On July 24th, 2026 With 0.40242 USD Special Dividend Per Share - Moomoo
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):